SCHEMBL16776194

SCHEMBL16776194

O=C(Nc1ccc(F)cn1)N1CCCNc2ccc(-c3ccnc(N4CCCC4)c3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 3/20 0.42
▸ PRKD3 O94806 1/20 0.40
▸ PRKD1 Q15139 1/20 0.40
▸ PRKD2 Q9BZL6 1/20 0.40
▸ FAAH O00519 1/20 0.40
▸ KARS1 Q15046 4/20 0.39
▸ CNR1 P21554 1/20 0.38
▸ DYRK1A Q13627 2/20 0.37
▸ AKT1 P31749 1/20 0.37
▸ MAPK1 P28482 2/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ CSF1R P07333 1/20 0.35
▸ MET P08581 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPY5R Q15761 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16776163 0.91 FGFR4 (0.40) FGFR4PRKD1PRKD2FAAHKARS1
SCHEMBL16776128 0.88 FGFR4 (0.38) FGFR4FAAHKARS1NPY5R
SCHEMBL16776049 0.88 FGFR4 (0.42) FGFR4KARS1CNR1CSF1RMET
SCHEMBL16776159 0.87 KARS1 (0.46) FGFR4PRKD3PRKD1PRKD2FAAH
SCHEMBL16776171 0.86 KARS1 (0.48) PRKD3PRKD1PRKD2KARS1DYRK1A
SCHEMBL16775866 0.86 FGFR4 (0.45) FGFR4NPY5R
SCHEMBL16776197 0.86 PRKD3 (0.40) PRKD3PRKD1PRKD2KARS1CNR1
SCHEMBL16775850 0.85 FGFR4 (0.44) FGFR4CSF1RMETKDRNPY5R
SCHEMBL16775936 0.84 FGFR4 (0.43) FGFR4CNR1ALDH1A1NPY5R
SCHEMBL16776137 0.83 FGFR4 (0.44) FGFR4DYRK1AMAPK1NPY5RWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152108-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2015-06-04 — — US disclosed
US-20150152108-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152108-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1754/4885PRKD3 1969/4885PRKD1 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback